Chemotherapy for osteosarcoma
1989
Chemotherapy for Osteosarcoma
Editorial
Evidence: moderate
Author Information
Author(s): R.L. Souhami
Primary Institution: University College and Middlesex School of Medicine
Conclusion
Intensive adjuvant chemotherapy has significantly improved long-term survival rates for osteosarcoma patients.
Supporting Evidence
- Only 25% of patients survived at 3 years when treated by amputation alone.
- 65% of patients are relapse-free at 5 years with intensive adjuvant chemotherapy.
- Shorter chemotherapy regimens may provide similar results to longer ones.
Takeaway
Doctors are finding better ways to treat a type of bone cancer called osteosarcoma, which helps more kids survive.
Methodology
The article discusses various clinical trials and treatment protocols for osteosarcoma, including the use of intensive chemotherapy and limb-sparing surgery.
Limitations
Trials with large sample sizes are impractical due to the rarity of the disease.
Participant Demographics
Primary osteosarcoma usually occurs in individuals aged 5 to 25.
Want to read the original?
Access the complete publication on the publisher's website